Research Paper Volume 15, Issue 5 pp 1628—1651
Integrative analysis to screen novel pyroptosis-related LncRNAs for predicting clinical outcome of glioma and validation in tumor tissue
- 1 Department of Neurosurgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450053, China
- 2 Department of Neurosurgery, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian 116000, China
- 3 Department of Neurosurgery, Cancer Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310006, China
- 4 Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China
Received: September 27, 2022 Accepted: February 20, 2023 Published: March 13, 2023
https://doi.org/10.18632/aging.204580How to Cite
Copyright: © 2023 Ma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: Pyroptosis, also known as inflammatory necrosis, is a programmed cell death that manifests itself as a continuous swelling of cells until the cell membrane breaks, leading to the liberation of cellular contents, which triggers an intense inflammatory response. Pyroptosis might be a panacea for a variety of cancers, which include immunotherapy and chemotherapy-insensitive tumors such as glioma. Several findings have observed that long non-coding RNAs (lncRNAs) modulate the bio-behavior of tumor cells by binding to RNA, DNA and protein. Nevertheless, there are few studies reporting the effect of lncRNAs in pyroptosis processes in glioma.
Methods: The principal goal of this study was to identify pyroptosis-related lncRNAs (PRLs) utilizing bioinformatic algorithm and to apply PCR techniques for validation in human glioma tissues. The second goal was to establish a prognostic model for predicting the overall survival patients with glioma. Predict algorithm was used to construct prognosis model with good diagnostic precision for potential clinical translation.
Results: Noticeably, molecular subtypes categorized by the PRLs were not distinct from any previously published subtypes of glioma. The immune and mutation landscapes were obviously different from previous subtypes of glioma. Analysis of the sensitivity (IC50) of patients to 30 chemotherapeutic agents identified 22 agents as potential therapeutic agents for patients with low riskscores.
Conclusions: We established an exact prognostic model according to the expression profile of PRLs, which may facilitate the assessment of patient prognosis and treatment patterns and could be further applied to clinical.
Abbreviations
lncRNAs: long non-coding RNAs; PRLs: pyroptosis-related lncRNAs; OS: overall survival; PRLPM: pyroptosis related lncRNA prognostic model; DEGs: differentially expressed genes; TMB: tumor mutational burden; TCGA: The Cancer Genome Atlas; CGGA: Chinese Glioma Genome Atlas; ICP: immune checkpoint.